Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Stem cell treatment a ‘breakthrough’ for equine lameness
“Arti-Cell® Forte contains stem cells that have been chondrogenically induced and therefore primed to develop into the cartilage cell lineage".
Arti-Cell Forte is the first stem cell-based medicine to receive marketing authorisation

The first stem cell-based medicine to receive marketing authorisation for the treatment of equine lameness has been launched by Boehringer Ingelheim.

Hailed as a ‘breakthrough medicine’ for degenerative joint disease in horses, Arti-Cell Forte is the first ‘ready-to-use’ stem cell-based product to be licensed in any veterinary species. It is also the only stem cell treatment to contain induced cells, marking a significant step in stem cell therapies and medicine as a whole.

“Arti-Cell® Forte contains stem cells that have been chondrogenically induced and therefore primed to develop into the cartilage cell lineage,” explained DR Amy Scott MRCVS, Boehringer Ingehlheim’s performance horse portfolio manager.

“Studies have shown that chondrogenically induced stem cells demonstrate an enhanced clinical outcome compared to un-induced stem cells in the treatment of joint disease in horses. This makes Arti-Cell® Forte a highly targeted and effective treatment for cartilage damage associated with degenerative joint disease.”

The medicine is available to veterinary practitioners direct from Boehringer Ingelheim. It is stored at ultra-low temperatures to maintain its two-year shelf life, either frozen at -70 ⁰C to -90 ⁰C (dry ice, -80 ⁰C freezer) or -196 ⁰C (liquid nitrogen) until immediately before injecting. 

Full training on storage and administration of the medicine is available from the Boehringer via face-to-face CPD at practice meetings or specific CPD events. For more information about these events, email vetenquiries@boehringer-ingelheim.com 

Become a member or log in to add this story to your CPD history

Face covering rules expanded

News Story 1
 New rules came into force in England on Saturday (8 August) making it mandatory for clients to wear a face covering in veterinary practices.

The rules, which also apply to cinemas, museums and places of worship, follow a recent spike in coronavirus cases. All clients in England must now wear a face covering when inside a veterinary practice unless they are exempt for age, health or equality reasons. 

Click here for more...
News Shorts
BSAVA webinars to shine the spotlight on selected journal papers

A free series of webinars that take a closer look at selected papers published in the Journal of Small Animal Practice has been produced by the BSAVA.

In the new BSAVA Science webinar series, authors of the featured papers discuss their results with a panel and how they may impact clinical practice. The authors then answer questions submitted by audience members.

The webinars are available via the BSAVA Webinar Library, covering four different papers. JSAP editor Nicola Di Girolamo, said: "Discussing the research with the authors - experts in their field - really helps to bring the papers to life."